These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 5008242)

  • 1. Preparation and antitumor activity of derivatives of 1-phenyl-3,3-dimethyltriazene.
    Lin YT; Loo TL
    J Med Chem; 1972 Feb; 15(2):201-3. PubMed ID: 5008242
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.
    Hatheway GJ; Hansch C; Kim KH; Milstein SR; Schmidt CL; Smith RN; Quinn FR
    J Med Chem; 1978 Jun; 21(6):563-74. PubMed ID: 671453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivatives.
    Giraldi T; Nisi C; Connors TA; Goddard PM
    J Med Chem; 1977 Jun; 20(6):850-3. PubMed ID: 874961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of antitumor activity of 1-[N, N-bis(2-chloroethyl) sulfamoylphenyl]-3,3-dialkyltriazenes.
    Lalezari I; Afghahi F
    J Pharm Sci; 1975 Apr; 64(4):698-9. PubMed ID: 1142087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and antitumor activity of alkyltriazenopyrazoles.
    Zakharieva RD; Spassova MK; Karaivanova MC; Golovinsky EV
    Arzneimittelforschung; 1984; 34(6):661-3. PubMed ID: 6541485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice.
    Hansch C; Hatheway GJ; Quinn FR; Greenberg N
    J Med Chem; 1978 Jun; 21(6):574-7. PubMed ID: 671454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triazenes of phenylbutyric, hydrocinnamic, phenoxyacetic, and benzoylglutamic acid derivatives.
    Shealy YF; Krauth CA; Opliger CE; Guin HW; Laster WR
    J Pharm Sci; 1971 Aug; 60(8):1192-8. PubMed ID: 5166659
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of cluster analysis in the development of structure-activity relations for antitumor triazenes.
    Dunn WJ; Greenberg MJ; Callejas SS
    J Med Chem; 1976 Nov; 19(11):1299-301. PubMed ID: 1003406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of 5-(3, 3-disubstituted-1-triazenyl) imidazole-4-carbonitriles.
    Shealy YF; O'Dell CA
    J Pharm Sci; 1975 Jun; 64(6):954-6. PubMed ID: 1133749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
    Lin AJ; Loo TL
    J Med Chem; 1978 Mar; 21(3):268-72. PubMed ID: 628002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative studies on the chemical stability and therapeutic effectiveness of water-insoluble 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) and its water-soluble hydrochloride against L1210 mouse leukemia.
    Woodman RJ; Kline I; Field RB; Gang M
    Cancer Chemother Rep; 1973; 57(4):383-91. PubMed ID: 4762437
    [No Abstract]   [Full Text] [Related]  

  • 12. Potential antitumor agents. 12. 9-Anilinoacridines.
    Atwell GJ; Cain BF; Seelye RN
    J Med Chem; 1972 Jun; 15(6):611-5. PubMed ID: 5030927
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
    Wilman DE; Cox PJ; Goddard PM; Hart LI; Merai K; Newell DR
    J Med Chem; 1984 Jul; 27(7):870-4. PubMed ID: 6737430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and activities of antitumor agents.
    Suami T; Machinami T; Hisamatsu T
    J Med Chem; 1979 Mar; 22(3):247-50. PubMed ID: 423206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential antitumor agents. 5. Methylated -(N)-heterocyclic carboxaldehyde thiosemicarbazones.
    Agrawal KC; Cushley RJ; Lipsky SR; Wheaton JR; Sartorelli AC
    J Med Chem; 1972 Feb; 15(2):192-5. PubMed ID: 5008241
    [No Abstract]   [Full Text] [Related]  

  • 16. [Antineoplastic agents on a 1-phenyl-3,3-dimethyltriazene base. I. Introduction].
    Matrka M; Zvĕrina V; Marhold J
    Cesk Farm; 1975 Jul; 24(6):262-6. PubMed ID: 1182834
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis of sparsomycin analogs as potential antitumor agents.
    Dubois RJ; Lin CC; Michel BL
    J Pharm Sci; 1975 May; 64(5):825-9. PubMed ID: 1151655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor imidazotetrazines. 14. Synthesis and antitumor activity of 6- and 8-substituted imidazo[5,1-d]-1,2,3,5-tetrazinones and 8-substituted pyrazolo[5,1-d]-1,2,3,5-tetrazinones.
    Lunt E; Newton CG; Smith C; Stevens GP; Stevens MF; Straw CG; Walsh RJ; Warren PJ; Fizames C; Lavelle F
    J Med Chem; 1987 Feb; 30(2):357-66. PubMed ID: 3806616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of novel, aminoalkanolic derivatives of 5,7-dihydroxy-2-phenylbenzopyran-4-on as the potential cytostatic agents.
    Mazur A; Balicka E; Zawadowski T; Miks B; Kawiak J
    Mater Med Pol; 1995; 27(4):157-9. PubMed ID: 9000841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,3-Dialkyl-3-acyltriazenes, a novel class of antineoplastic alkylating agents.
    Smith RH; Scudiero DA; Michejda CJ
    J Med Chem; 1990 Sep; 33(9):2579-83. PubMed ID: 2391696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.